A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial of sodium oligomannate for #br# mild-to-moderate Alzheimer disease

XIAO Shi-fu

PDF(194 KB)
Chinese Journal of Pharmacology and Toxicology
PDF(194 KB)
Chinese Journal of Pharmacology and Toxicology ›› 2019, Vol. 33 ›› Issue (6) : 403-403.

A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial of sodium oligomannate for #br# mild-to-moderate Alzheimer disease

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2019, 33(6): 403-403

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(194 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉